Bioconnexions Consulting

Both Ian and Colin have been part of, and led, teams responsible for the development and commercialization of assays to diagnostic targets such as CD10 (56C6), Class II 510k devices for estrogen and progesterone receptors, as well as companion diagnostics for HER2.

Our goal: By reviewing projects at any stage of the product development cycle we can identify the road blocks and issues that otherwise go unseen. Through our experience, use of industry "best practice" and connection to clinicians and scientists, we are well placed to resolve your issues.